Clinical Experience With Infliximab for Crohn’s Disease: The First 100 Patients in Edmonton, Alberta

Canadian Journal of Gastroenterology
doi 10.1155/2002/379307
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Infliximab Treatment Time and the Mucosal Healing Effect in Pediatric Patients With Severe Crohn’s Disease – Own Experience

Przeglad Gastroenterologiczny
Gastroenterology
2012English

Infliximab Versus Adalimumab in Patients With Biologic-Naïve Crohn’s Disease: Is the Difference Real?

Digestive Diseases and Sciences
PhysiologyGastroenterology
2018English

Fulminant Legionellosis in Two Patients Treated With Infliximab for Crohn’s Disease: Case Series and Literature Review

Canadian Journal of Gastroenterology
2009English

Subtherapeutic Concentrations of Infliximab and Adalimumab Are Associated With Increased Disease Activity in Crohn’s Disease

Therapeutic Advances in Gastroenterology
Gastroenterology
2018English

Individualized Treatment With Infliximab Therapy in Children With Crohn’s Disease Support Shorter Time Intervals Between Infusions

Journal of Drug Assessment
2012English

Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2018English

Exclusive Enteral Nutrition Versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease

Gastroenterology Research and Practice
HepatologyGastroenterology
2017English

Comparison of Scheduled and Episodic Treatment Strategies of Infliximab in Crohn’s Disease

Gastroenterology
HepatologyGastroenterology
2004English

Efficacy of Infliximab Biosimilars in Patients With Crohn's Disease

The Lancet
Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy